MHRA Registration Secured for AI-Powered Haemodialysis System; UK Exports Planned from January 2027
The company's haemodialysis system has secured registration with the MHRA, London, UK, covering Renalyx Health Systems Pvt. Ltd. as manufacturer, for institutional and home use under GMDN Code 58131.
By ScoutQuest · · 1 min read
- Product Registration
- Haemodialysis system secured MHRA registration, London, UK
- Manufacturer
- Renalyx Health Systems Pvt. Ltd.
- Device Code
- GMDN Code 58131
- Use Cases
- Institutional and home use
- Export Timeline
- Early January 2027
What was announced
The company informed BSE that its haemodialysis system has secured registration with the Medicines & Healthcare products Regulatory Agency (MHRA), London, UK. The registration covers Renalyx Health Systems Pvt. Ltd. as a manufacturer, with its haemodialysis system for institutional and home use registered under GMDN Code 58131.
Market plans
- The company states it will start exporting its machine to the UK and UK-ally countries from early January 2027.
- It positions this as the first Indian company to achieve this milestone in the context of the India-UK Free Trade Agreement.
- A dual pathway is proposed: supplying Renalyx systems to healthcare providers, and establishing and operating its own dialysis centres.
- Deployment in UK-allied markets is described as being explored, subject to applicable regulatory, clinical and market-access requirements.
The product
The offering is described as an integrated renal-care ecosystem rather than a standalone machine. At its core is the Renalyx haemodialysis machine, supported by RenalOS, an AI-powered clinical intelligence platform. The system is designed for real-time monitoring of treatment parameters, predictive alerts, data-driven decision support during sessions and remote patient monitoring beyond the dialysis centre.
Important qualifier
The update notes that the MHRA expressly clarifies that this registration does not itself constitute accreditation, certification or approval by the UK Competent Authority.
How investors may read it
The announcement is a regulatory-registration and business-intent update. Language such as "explore", "evaluating" and "proposed model" runs through the international plans. The update carries no order value, revenue contribution, capex or timeline for centre operations, so the financial impact cannot be measured from this intimation. Investors may track whether exports commence as indicated and whether any order or revenue disclosures follow.
Also from Lords Mark Industries
US FDA registration for 200+ products; Silvassa expansion completed ahead of schedule
23 Oct 2026
Board to consider Rs. 100 Crore unsecured loan from promoter with option to convert into equity
19 Oct 2026
Board approves appointment of Whole-Time Company Secretary and Compliance Officer
14 Oct 2026
More numbers
- GMDN Code for registered haemodialysis systemGMDN Code 58131
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.